Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:4 Number:12 ISSN#:2563-5476
Author Verified
RCT
ACE Report #4343
Ace Report Cover Tumour

Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma

Cancer. 2012 Dec 1;118(23):5888-93

Contributing Authors: NM Bernthal N Federman FR Eilber SD Nelson JJ Eckardt FC Eilber WD Tap

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.